EBV (BRLF1)
Online Inquiry
| CAT# | PPO-H011 |
| Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Purity | >70% (HPLC-MS) |
| Areas of Interest | Infection, Cancer, Hodgkin's lymphoma, Burkitt's lymphoma, Nasopharyngeal carcinoma, Dermatomyositis, Systemic lupus erythematosus, Rheumatoid arthritis, Sj?gren's syndrome, Multiple sclerosis |
| Size | 1 vial containing 15 nmol ( 25μg) per peptide |
SwissProt ID | P03209 |
Format | Freeze dried in amber type glass vial |
NumberOfPeptides | 149 |
Organism | Epstein-Barr virus (HHV-4) |
Specifications | Peptide scan (15mers with 11 aa overlap) |
Protein Length | 605 |
Protein Name | Transcription activator BRLF1 |
References | 1."PepMixTM Peptide Pools for Clinical Applications: T cell therapy for viral infections after hematopoietic stem cell transplant"
Leen et al, Application Note (2012)
2."Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV". Mellberg et al., AIDS Research and Therapy (2011))
3."A Whole Blood Monokine-based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response"
Chakera et al., Journal of Translational Medicine (2011)
4."Effective and Long-term Control of EBV PTLD After Transfer of Peptide-Selected T Cells". Moosmann et al., BLOOD (2010) |
Write a review
Ask a question
My Review for EBV (BRLF1)
Required fields are marked with *
×
Ask a Question for EBV (BRLF1)
Required fields are marked with *
×
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
